On March 26, 2025, Vivani announced promising preclinical data for NPM-139, its subdermal semaglutide implant that is under development for chronic weight management in obese and overweight ...

On March 26, 2025, Vivani announced promising preclinical data for NPM-139, its subdermal semaglutide implant that is under development for chronic weight management in obese and overweight ...

On March 26, 2025, Vivani announced promising preclinical data for NPM-139, its subdermal semaglutide implant that is under development for chronic weight management in obese and overweight ...

Vivani’s lead program, NPM-115, is a six-month, subdermal, GLP-1 (exenatide) implant under development for chronic weight management in obese or overweight individuals. Vivani’s emerging pipeline ...

Now onto our second proprietary program in regenerative medicine, our regenerative breast implant. This quarter, we continue to advance our preclinical testing of our commercial-sized breast ...

The annual Grindfest meetup sees biohackers display implants and augmentations. As magician and biohacker Anastasia Synn approaches her home, she tries to open the front door and finds it locked.

The regenerative breast implant program has progressed through preclinical testing of 200cc commercial-sized implants, showcasing promising results such as tissue integration, vascularization ...

NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration with expected once or twice-yearly dosing NPM-139 is a miniature, subdermal implant in development ...

NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration with expected once or twice-yearly dosing NPM-139 is a miniature, subdermal implant in ...